RAINFOL-03 | NCT07166094

APGOT-EN3: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator’s Choice (IC) in Patients with Endometrial Cancer (EC) After Platinum-Based Chemotherapy and PD(L)-1 Therapy.

RAINFOL-03 | NCT071660942026-09-16T15:56:28+10:00

REZOLV3R | ACTRN12624000288527

The REZOLV3R trial compares post treatment paracentesis free survival time between each treatment group (bevacizumab or control).  The aim is to improve quality of life and optimise management of patients with advanced cancers with recurrent malignant ascites in the [...]

REZOLV3R | ACTRN126240002885272026-06-12T09:37:02+10:00

DOVE | APGOT-OV7/ENGOT-ov80

The DOVE trial is a Phase II, randomised study evaluating the efficacy and safety of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynaecological clear cell carcinoma.

DOVE | APGOT-OV7/ENGOT-ov802026-03-12T21:02:42+11:00

EN.10/TAPER | NCT05640999

The primary objective of this study is to estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status.

EN.10/TAPER | NCT056409992026-06-12T09:36:53+10:00

PEACE | ACTRN12621001031853

PEACE aims to determine the feasibility of collecting information from women, and their careers, with advanced gynaecological cancer about their experiences, satisfaction with care and symptom management towards end of life. Information collected focuses on how both patients and [...]

PEACE | ACTRN126210010318532026-06-12T09:35:20+10:00
Go to Top